Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1958 1
1960 1
1964 2
1965 5
1966 1
1968 1
1969 3
1970 6
1971 7
1972 5
1973 3
1974 7
1975 15
1976 22
1977 11
1978 9
1979 12
1980 12
1981 19
1982 23
1983 26
1984 21
1985 22
1986 29
1987 38
1988 50
1989 75
1990 120
1991 183
1992 262
1993 338
1994 450
1995 451
1996 446
1997 435
1998 428
1999 429
2000 394
2001 358
2002 354
2003 304
2004 288
2005 302
2006 271
2007 274
2008 253
2009 249
2010 257
2011 222
2012 235
2013 270
2014 263
2015 284
2016 346
2017 359
2018 326
2019 408
2020 433
2021 433
2022 558
2023 554
2024 250

Text availability

Article attribute

Article type

Publication date

Search Results

11,429 results

Results by year

Filters applied: . Clear all
Page 1
Lp(a): When and how to measure it.
Cegla J, France M, Marcovina SM, Neely RDG. Cegla J, et al. Ann Clin Biochem. 2021 Jan;58(1):16-21. doi: 10.1177/0004563220968473. Epub 2020 Oct 28. Ann Clin Biochem. 2021. PMID: 33040574 Free PMC article. Review.
The major challenges relate to its size heterogeneity and related issues including (1) use of appropriate calibrators (2) standardization of calibration protocols (3) traceability and (4) reporting units. In the UK, results from the current EQA schemes for lipoprotein(a …
The major challenges relate to its size heterogeneity and related issues including (1) use of appropriate calibrators (2) standardization of …
LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics.
Tasdighi E, Adhikari R, Almaadawy O, Leucker TM, Blaha MJ. Tasdighi E, et al. Annu Rev Pharmacol Toxicol. 2024 Jan 23;64:135-157. doi: 10.1146/annurev-pharmtox-031023-100609. Epub 2023 Jul 28. Annu Rev Pharmacol Toxicol. 2024. PMID: 37506332 Free article. Review.
Lipoprotein(a) [Lp(a)] is a molecule bound to apolipoprotein(a) with some similarity to low-density lipoprotein cholesterol (LDL-C), which has been found to be a risk factor for cardiovascular disease (CVD). Lp(a) appears to induce inflam …
Lipoprotein(a) [Lp(a)] is a molecule bound to apolipoprotein(a) with some similarity to low-density lipoprotein …
A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies.
Tsimikas S. Tsimikas S. J Am Coll Cardiol. 2017 Feb 14;69(6):692-711. doi: 10.1016/j.jacc.2016.11.042. J Am Coll Cardiol. 2017. PMID: 28183512 Free article. Review.
Evidence that elevated lipoprotein(a) (Lp[a]) levels contribute to cardiovascular disease (CVD) and calcific aortic valve stenosis (CAVS) is substantial. ...These approaches will allow testing of the "Lp(a) hypothesis" in clinical trials. …
Evidence that elevated lipoprotein(a) (Lp[a]) levels contribute to cardiovascular disease (CVD) and calcific aor …
Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment.
Lampsas S, Xenou M, Oikonomou E, Pantelidis P, Lysandrou A, Sarantos S, Goliopoulou A, Kalogeras K, Tsigkou V, Kalpis A, Paschou SA, Theofilis P, Vavuranakis M, Tousoulis D, Siasos G. Lampsas S, et al. Molecules. 2023 Jan 18;28(3):969. doi: 10.3390/molecules28030969. Molecules. 2023. PMID: 36770634 Free PMC article. Review.
Lipoprotein(a) (Lp(a)) is a low-density lipoprotein (LDL) cholesterol-like particle bound to apolipoprotein(a). Increased Lp(a) levels are an independent, heritable causal risk factor for atherosclerotic cardiovascular disease (ASCVD) as …
Lipoprotein(a) (Lp(a)) is a low-density lipoprotein (LDL) cholesterol-like particle bound to apolipoprotein(a). …
Genetic variants associated with Lp(a) lipoprotein level and coronary disease.
Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M; PROCARDIS Consortium. Clarke R, et al. N Engl J Med. 2009 Dec 24;361(26):2518-28. doi: 10.1056/NEJMoa0902604. N Engl J Med. 2009. PMID: 20032323 Free article.
Both variants were strongly associated with an increased level of Lp(a) lipoprotein, a reduced copy number in LPA (which determines the number of kringle IV-type 2 repeats), and a small Lp(a) lipoprotein size. ...CONCLUSIONS: We identifie …
Both variants were strongly associated with an increased level of Lp(a) lipoprotein, a reduced copy number in LP …
Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis.
Boffa MB. Boffa MB. Atherosclerosis. 2022 May;349:72-81. doi: 10.1016/j.atherosclerosis.2022.04.009. Atherosclerosis. 2022. PMID: 35606079 Review.
Elevated plasma concentrations of lipoprotein(a) (Lp(a)) are a causal risk factor for the development of atherothrombotic disorders including coronary heart disease. ...Accordingly, different prothrombotic mechanisms for Lp(a) must be con …
Elevated plasma concentrations of lipoprotein(a) (Lp(a)) are a causal risk factor for the development of atherot …
Lipoprotein(a) and Cardiovascular Diseases - Revisited.
Jang AY, Han SH, Sohn IS, Oh PC, Koh KK. Jang AY, et al. Circ J. 2020 May 25;84(6):867-874. doi: 10.1253/circj.CJ-20-0051. Epub 2020 Apr 24. Circ J. 2020. PMID: 32336721 Free article. Review.
Two decades ago, it was recognized that lipoprotein(a) (Lp(a)) concentrations were elevated in patients with cardiovascular disease (CVD). However, the importance of Lp(a) was not strongly established due to a lack of both Lp(a …
Two decades ago, it was recognized that lipoprotein(a) (Lp(a)) concentrations were elevated in patients with car …
Therapy of hyper-Lp(a).
Kostner KM, Kostner GM. Kostner KM, et al. Handb Exp Pharmacol. 2005;(170):519-36. doi: 10.1007/3-540-27661-0_19. Handb Exp Pharmacol. 2005. PMID: 16596813 Review.
Lipoprotein (a) [Lp(a)] appears to be one of the most atherogenic lipoproteins. ...There is without doubt a strong need to concentrate on the development of specific medications to selectively target Lp(a) biosynthesis, Lp(a …
Lipoprotein (a) [Lp(a)] appears to be one of the most atherogenic lipoproteins. ...There is without doubt a stro …
Lp(a) and the Risk for Cardiovascular Disease: Focus on the Lp(a) Paradox in Diabetes Mellitus.
Kostner KM, Kostner GM. Kostner KM, et al. Int J Mol Sci. 2022 Mar 25;23(7):3584. doi: 10.3390/ijms23073584. Int J Mol Sci. 2022. PMID: 35408941 Free PMC article. Review.
Lipoprotein(a) (Lp(a)) is one of the strongest causal risk factors of atherosclerotic disease. ...In vitro studies on the catabolism of Lp(a) have revealed that Lp(a) binds to several specific lipoprotein receptors; however, …
Lipoprotein(a) (Lp(a)) is one of the strongest causal risk factors of atherosclerotic disease. ...In vitro studi …
Statins and Lp(a): The plot thickens.
Enkhmaa B, Berglund L. Enkhmaa B, et al. Atherosclerosis. 2019 Oct;289:173-175. doi: 10.1016/j.atherosclerosis.2019.07.021. Epub 2019 Aug 6. Atherosclerosis. 2019. PMID: 31443913 Free PMC article. No abstract available.
11,429 results
You have reached the last available page of results. Please see the User Guide for more information.